Development and clinical testing of a bank of CD30.CAR-EBVSTs. Allogeneic CD30.CAR transduced EBVSTs (CD30.CAR-EBVSTs) will kill (1) recipient activated alloreactive T cells that upregulate CD30 upon activation and (2) CD30-expressing lymphoma cells. EBVSTs will not cause GVHD.